---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-067043"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:16:06.843293+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q1 net loss $2.1M; cash only to June 2025

## Summary
- Cash and equivalents $3.7M at March 31, 2025, down from $6.5M at Dec 31, 2024.
- Net loss $2.1M ($2.11 per share) vs $2.7M ($39.37 per share) in Q1 2024.
- Operating cash burn $2.8M in Q1 2025, same as Q1 2024.
- Management says current cash sufficient only through June 2025.
- New indication for Gemini in severe burns; topline PRIME Phase 1b data expected summer 2025.

## SEC filing metadata
- accession: 0000950170-25-067043
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/0000950170-25-067043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-067043
- JSON: https://secwatch.observer/filing/0000950170-25-067043.json
- Plain text: https://secwatch.observer/filing/0000950170-25-067043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.